241 related articles for article (PubMed ID: 24085765)
1. Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.
Bernot KM; Nemer JS; Santhanam R; Liu S; Zorko NA; Whitman SP; Dickerson KE; Zhang M; Yang X; McConnell KK; Ahmed EH; Muñoz MR; Siebenaler RF; Marcucci GG; Mundy-Bosse BL; Brook DL; Garman S; Dorrance AM; Zhang X; Zhang J; Lee RJ; Blum W; Caligiuri MA; Marcucci G
Blood; 2013 Nov; 122(23):3778-83. PubMed ID: 24085765
[TBL] [Abstract][Full Text] [Related]
2. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.
Zorko NA; Bernot KM; Whitman SP; Siebenaler RF; Ahmed EH; Marcucci GG; Yanes DA; McConnell KK; Mao C; Kalu C; Zhang X; Jarjoura D; Dorrance AM; Heerema NA; Lee BH; Huang G; Marcucci G; Caligiuri MA
Blood; 2012 Aug; 120(5):1130-6. PubMed ID: 22674806
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
[TBL] [Abstract][Full Text] [Related]
4. FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
Nasilowska-Adamska B; Solarska I; Paluszewska M; Malinowska I; Jedrzejczak WW; Warzocha K
Ann Hematol; 2014 Apr; 93(4):577-93. PubMed ID: 24030729
[TBL] [Abstract][Full Text] [Related]
5. Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML.
Zhang B; Nguyen LXT; Zhao D; Frankhouser DE; Wang H; Hoang DH; Qiao J; Abundis C; Brehove M; Su YL; Feng Y; Stein A; Ghoda L; Dorrance A; Perrotti D; Chen Z; Han A; Pichiorri F; Jin J; Jovanovic-Talisman T; Caligiuri MA; Kuo CJ; Yoshimura A; Li L; Rockne RC; Kortylewski M; Zheng Y; Carlesso N; Kuo YH; Marcucci G
J Hematol Oncol; 2021 Aug; 14(1):122. PubMed ID: 34372909
[TBL] [Abstract][Full Text] [Related]
6. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group.
Shimada A; Taki T; Tabuchi K; Taketani T; Hanada R; Tawa A; Tsuchida M; Horibe K; Tsukimoto I; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):264-9. PubMed ID: 17763464
[TBL] [Abstract][Full Text] [Related]
7. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
[TBL] [Abstract][Full Text] [Related]
8. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.
Chien W; Sun QY; Ding LW; Mayakonda A; Takao S; Liu L; Lim SL; Tan KT; Garg M; De Sousa Maria Varela A; Xiao J; Jacob N; Behrens K; Stocking C; Lill M; Madan V; Hattori N; Gery S; Ogawa S; Wakita S; Ikezoe T; Shih LY; Alpermann T; Haferlach T; Yang H; Koeffler HP
Leukemia; 2017 Mar; 31(3):762-766. PubMed ID: 27881871
[No Abstract] [Full Text] [Related]
11. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).
Sun QY; Ding LW; Tan KT; Chien W; Mayakonda A; Lin DC; Loh XY; Xiao JF; Meggendorfer M; Alpermann T; Garg M; Lim SL; Madan V; Hattori N; Nagata Y; Miyano S; Yeoh AE; Hou HA; Jiang YY; Takao S; Liu LZ; Tan SZ; Lill M; Hayashi M; Kinoshita A; Kantarjian HM; Kornblau SM; Ogawa S; Haferlach T; Yang H; Koeffler HP
Leukemia; 2017 Jan; 31(1):1-10. PubMed ID: 27389053
[TBL] [Abstract][Full Text] [Related]
12. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
Christiansen DH; Pedersen-Bjergaard J
Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
[TBL] [Abstract][Full Text] [Related]
13. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
15. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
16. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
[TBL] [Abstract][Full Text] [Related]
17. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
18. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
19. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A; Taki T; Koga D; Tabuchi K; Tawa A; Hanada R; Tsuchida M; Horibe K; Tsukimoto I; Adachi S; Kojima S; Hayashi Y
Int J Hematol; 2012 Oct; 96(4):469-76. PubMed ID: 22915059
[TBL] [Abstract][Full Text] [Related]
20. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]